Compare EPAM Systems Inc (EPAM) vs Hims and Hers Health Inc (HIMS) Price & Performance

EPAM Systems trades at $114.00, up 5.24% today, with a bearish technical signal but strong fundamentals. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $3.38 surpassing the $3.16 expectation. Revenue grew to $5.46 billion in 2025, though net income margin compressed to 6.92%. The company maintains solid cash flow from operations of $654.93 million and a healthy balance sheet with $1.29 billion in cash.

The outlook is mixed; analyst consensus is a Buy with a $119.00 price target, but near-term revenue headwinds and AI disruption risks persist. Investment opportunity lies in attractive valuation multiples (P/E 15.45, EV/EBITDA 7.25) and potential share repurchases urged by activists. Key risks include slower North American growth and competitive pressures in digital transformation services.

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.